Log in or Sign up for Free to view tailored content for your specialty!
Cell Therapy News
FDA grants fast track designation to ATR-04 for cancer therapy-induced skin rash
The FDA has granted fast track designation to topically applied ATR-04 for the treatment of moderate to severe epidermal growth factor receptor inhibitor-associated dermal toxicity, Azitra announced in a press release.
Axi-cel ‘can be curative’ for large B-cell lymphoma, but nonrelapse mortality a concern
A real-world evaluation of axicabtagene ciloleucel for individuals with relapsed or refractory large B-cell lymphoma showed 5-year OS, PFS and disease-specific survival rates comparable to those observed in clinical trials.
Risk for second primary malignancies no greater with CAR-T than other standard therapies
Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.
Log in or Sign up for Free to view tailored content for your specialty!
Individualized neoantigen therapy could be ‘huge leap’ toward personalized medicine
A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.
Looking back, looking forward: Penn’s CAR-T program continues path of progress
In 2018, at the height of the chimeric antigen receptor T-cell therapy revolution and in the heart of its implementation, Healio’s Cell Therapy Next staff went onsite to University of Pennsylvania’s newly minted center.
Removing CD5 gene improves CAR-T expansion, antitumor capabilities
Deleting the CD5 gene from chimeric antigen receptor T cells improved their expansion, durability and tumor-killing capabilities, according to study findings.
FDA clears development of drug to treat cancer therapy-induced skin rash
The FDA has cleared an investigational new drug application for a first-in-human phase 1/2 study of ATR-04 for moderate to severe dermal toxicity from epidermal growth factor receptor inhibitors, Azitra Inc. announced in a press release.
Tisagenlecleucel ‘can be curative’ for some children with acute leukemia
Children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia increasingly receive tisagenlecleucel in earlier settings when they have lower disease burden, according to findings presented at ASCO Annual Meeting.
FDA approves T-cell immunotherapy for advanced synovial sarcoma
The FDA granted accelerated approval to afamitresgene autoleucel for certain adults with unresectable or metastatic synovial sarcoma.
Findings highlight ‘critical importance’ of infectious complications after CAR-T
Infections are the primary cause of nonrelapse mortality among individuals who undergo chimeric antigen receptor T-cell therapy, according to study results.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read